Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics
MNK Price/Volume Stats
| Current price | $0.35 | 52-week high | $18.10 |
| Prev. close | $0.34 | 52-week low | $0.30 |
| Day low | $0.35 | Volume | 1,472 |
| Day high | $0.35 | Avg. volume | 1,973,344 |
| 50-day MA | $1.01 | Dividend yield | N/A |
| 200-day MA | $5.61 | Market Cap | 4.62M |
MNK Stock Price Chart Interactive Chart >
Mallinckrodt plc Ordinary Shares (MNK) Company Bio
Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.
Latest MNK News From Around the Web
Below are the latest news stories about MALLINCKRODT PLC that investors may wish to consider to help them evaluate MNK as an investment opportunity.
Drugmaker Mallinckrodt files for second bankruptcy in USDrugmaker Mallinckrodt on Monday filed for its second bankruptcy in three years in the United States, with a restructuring plan that would cut $1 billion from what it owes to victims of the opioid crisis. The New York Stock Exchange said it has suspended trading in Mallinckrodt's ordinary shares with immediate effect and has commenced proceedings to delist them from the exchange. Mallinckrodt, which makes both branded and generic drugs, had first filed for bankruptcy in 2020 to address its high debt load, litigation over its marketing of highly addictive generic opioids and disputes over its drug pricing. |
UPDATE 3-Drugmaker Mallinckrodt files for second bankruptcy in USDrugmaker Mallinckrodt on Monday filed for its second bankruptcy in three years in the United States, with a restructuring plan that would cut $1 billion from what it owes to victims of the opioid crisis. The New York Stock Exchange said it has suspended trading in Mallinckrodt's ordinary shares with immediate effect and has commenced proceedings to delist them from the exchange. Mallinckrodt, which makes both branded and generic drugs, had first filed for bankruptcy in 2020 to address its high debt load, litigation over its marketing of highly addictive generic opioids and disputes over its drug pricing. |
Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid ObligationsMallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement ("RSA") the Company previously entered into with more than 85% of each of the Company's first and second lien debtholders and the Opioid Master Disbursement Trust II (the "Trust"), as announced on August 23, 2023. |
PRESS DIGEST- Wall Street Journal - Aug 24The following are the top stories in the Wall Street Journal. - Woodside Energy reached a preliminary deal with disaffected workers at some of its natural gas export facilities in Australia, a move that could head off a walkout that risked disrupting global gas supply and jolting worldwide energy prices. - Shortly after 6 p.m. Moscow time on Wednesday, an Embraer jet carrying Wagner paramilitary group owner Yevgeny Prigozhin, who led a short-lived June uprising that challenged Russian President Vladimir Putin's authority, abruptly disappeared from flight-tracking radar screens northwest of Moscow. |
PRESS DIGEST-New York Times business news - Aug 24The following are the top stories on the New York Times business pages. - Mark Thompson, a former top executive at The New York Times and the BBC, is one of several people in talks to lead CNN. - Drugmaker Mallinckrodt said on Wednesday it expects to file for a second bankruptcy in the coming days, after reaching a debt reduction deal that would cut $1 billion from the amount it owes to victims of the opioid crisis. |
MNK Price Returns
| 1-mo | N/A |
| 3-mo | -69.30% |
| 6-mo | -93.69% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -95.48% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Continue Researching MNK
Want to see what other sources are saying about Mallinckrodt plc's financials and stock price? Try the links below:Mallinckrodt plc (MNK) Stock Price | Nasdaq
Mallinckrodt plc (MNK) Stock Quote, History and News - Yahoo Finance
Mallinckrodt plc (MNK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...